(NASDAQ: SCPH) Scpharmaceuticals's forecast annual revenue growth rate of 65.3% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Scpharmaceuticals's revenue in 2025 is $41,982,000.On average, 2 Wall Street analysts forecast SCPH's revenue for 2025 to be $4,059,703,108, with the lowest SCPH revenue forecast at $3,896,047,976, and the highest SCPH revenue forecast at $4,223,358,240. On average, 2 Wall Street analysts forecast SCPH's revenue for 2026 to be $6,762,652,382, with the lowest SCPH revenue forecast at $5,970,772,712, and the highest SCPH revenue forecast at $7,554,532,052.
In 2027, SCPH is forecast to generate $10,120,222,183 in revenue, with the lowest revenue forecast at $8,573,417,227 and the highest revenue forecast at $11,667,027,138.